RNXT renovorx.com: שווי עסקי להכנסות

Patent protection for chemotherapy delivery systems minimizes risks, and the current GURU.Markets chart for RenovoRx, Inc. (RNXT) includes the company's price-to-sales ratio, which currently stands at 14611.51. RenovoRx, Inc. (RNXT) revenues are based on the sale of catheters for treating gastric tumors, while its environmental policy relies on the safe disposal of polymers and standard office recycling.
פילוחי מדדים פיננסיים ומדדי שוק עבור RenovoRx Corp (RNXT)

To select assets with a high margin of safety, the enterprise value-to-revenue ratio is used, which adjusts market capitalization for net debt to assess the real price per unit of income. In the case of RenovoRx, Inc. (RNXT), the absence of commercial sales against a backdrop of rising R&D costs makes the EV/Sales metric an indicator of the speculative value of future technologies rather than current operational efficiency.